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A B S T R A C T   
MicroRNAs (miRNAs) are endogenous, non-coding, single-stranded and tiny RNAs that modulate several bio-
logical functions, more importantly, the pathophysiology of numerous human cancers. They are bound with 
target mRNAs and thereby regulate gene expression at post-transcriptional levels. MiRNAs can either trigger 
cancer progression as an oncogene or alleviate it as a tumor suppressor. Abnormal expression of microRNA-1297 
(miR-1297) has been noticed in several human cancers suggesting a distinct role for the miRNA in tumorigenesis. 
More specifically, it is both up-regulated and down-regulated in various cancers suggesting that it can act as both 
tumor suppressor and oncogene. This review systematically highlights the different roles of miR-1297 in the 
pathophysiology of human cancers, explains the mechanisms underlying miR-1297-mediated tumorigenesis, and 
discusses its potential prognostic, diagnostic, and therapeutic importance.   
1. Introduction 
Cancer is one of the major public health concerns worldwide and is 
considered to be the 2nd leading cause of death in the United States. The 
statistics on 2019 indicate that 1762,450 new cancer cases and 606,880 
cancer deaths were recorded in the United States [1], and the corre-
sponding economic losses were estimated to be $94.4 billion in 2015 
[2]. These data highlight the importance of seeking novel and efficient 
prognostic, diagnostic, and therapeutic strategies. 
Despite the massive efforts, timely diagnosis and treatment of cancer 
still continue to be a serious challenge [1]. In a massive effort to explore 
the mechanisms of carcinogenesis, researchers have recently discovered 
that numerous genes are dysregulated at the beginning and progression 
of tumors, including tumor suppressors’ shutdown as well as uncon-
trolled activation of oncogenes and proliferation-related signaling 
pathways [3]. The recently published papers confirm implication of 
miRNAs in regulation of functional genes associated with oncogenesis 
through activation or inactivation of oncogenes and targeting cell 
signaling pathways [4–6]. Considering their crucial roles in the patho-
physiology of various cancers, the involvement of miRNAs in human 
malignancies should be fully elucidated, to have broad insight into the 
oncogenesis and enhance therapeutic strategies. 
MiRNAs, a group of highly conserved, single-stranded, endogenous, 
non-coding, small RNAs consisting of 21–23 nucleotides, are post- 
transcriptional regulators of gene expression by base-pairing with 
mRNA molecules in the 3′ untranslated region (3′-UTR), controlling the 
translation process of the target mRNA. The level of complementarity 
between miRNAs and the target mRNAs determines whether the trans-
lation process is blocked or less frequently the target gene may be 
degraded [7–9]. MiRNAs make up 1–5% of the human genome, acting as 
a regulator of at least 30% of protein-coding genes [10]. Firm evidence 
indicates that miRNAs are potentially involved in the pathophysiology 
of several diseases, including cancer [11–14], atherosclerosis [15–18], 
varicose disease [19], obesity [20], and neonatal sepsis [21]. Also, they 
play a crucial role in numerous biological functions including, (but not 
limited to) cell growth [22], apoptosis [23–25,132], lipid and 
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lipoprotein metabolism [26,27], hemostasis [28], and immune re-
sponses [9,29]. MiRNAs can be detected in different tissues (e.g., tumor 
tissues), the circulation, and serum, which enables them to be employed 
as an excellent tool for non-invasive and quick diagnoses of many dis-
eases, more importantly, cancer [30]. For instance, except for leukemia 
which is approachable and easily sampled, other types of tumors 
particularly solid ones require biopsy and surgery for a definite diag-
nosis. Unfortunately, these invasive techniques are usually used when 
the disease is at the end-stage. Therefore, miRNAs may be of grave 
importance for timely and non-invasive diagnosis of malignancies [31, 
32]. MiRNAs also contain potential therapeutic capacity; as evidence, 
miR-208/499 and miR-195 have been introduced as a preclinical ther-
apy for cardiovascular disease, while miR-34 and let-7 for cancer. Mir-
avirsen (codenamed SPC3649), antisense to miR-122 has been entered 
the phase II clinical trials to treat hepatitis C virus infection [33–35]. 
2. MiR-1297 
MiR-1297 is a small RNA particle comprised of 17 nucleotides, and 
the following sequence 5′UUCAAGUAAUUCAGGUG3′ located on the 
13q14.3 chromosome (Fig. 1). Consistent with the canonical miRNA 
biogenesis pathway, miR-1297 is biosynthesized in the nucleus and 
cytoplasm through different steps. Initially, miR-1297 is transcribed in a 
large double-strand RNA by the RNA polymerase II which is called Pri- 
mir-1297. Then, an enzyme called Drosha and its related protein, 
DiGeorge Syndrome Critical Region 8 (DGCR8) turn Pri-mir-1297 into 
Pre-mir-1297 and then it is transferred to the cytoplasm. In the cyto-
plasm, Pre-mir-1297 is affected by DICER enzyme and the proteins 
AGO2 (Argonaute family protein) and TRBP [trans-activation response 
(TAR) RNA binding protein] which lead to formation of mature mir- 
1297. Now, single-stranded mir-1297 can be guided to the target 
where it can activate or inactivate one or more functional genes [10]. 
Within the past decade, the role of miRNAs in cancer has been well- 
reviewed [31,36–40]. However, papers dealing with a specific miRNA 
are relatively rare. A glance at major scientific databases clearly shows 
that miR-1297 has aroused tremendous research interest, and its roles in 
the pathophysiology of different diseases are currently being investi-
gated (Table 1). As evidence, there were only two papers in 2012 in 
PubMed, and this was elevated to 15 in 2020. Considering the expo-
nential growth of published papers about miR-1297, it is necessary to 
summarize the most recent advances. Therefore the current study was 
conducted to give a comprehensive insight into the potential roles of 
miR-1297 in the prognosis, diagnosis, and therapy of various cancers. 
Furthermore, the paper briefly discusses the genes targeted by miR-1297 
and summarizes molecular studies conducted on the effect of miR-1297 
on different molecular pathways offering the opportunity to identify 
novel biomarkers and molecular mechanisms. 
3. MiR-1297 in cancerous diseases 
MiR-1297 as a newly-discovered miRNA has been proved to play a 
crucial role in tumorigenesis of numerous human malignancies 
including, colorectal cancer (CRC), hepatocellular carcinoma (HCC), 
cholangiocarcinoma (CCA), esophagus squamous cell carcinoma 
(ESCC), oral squamous cell carcinoma (OSCC), cervical cancer (CC), 
testicular germ cell tumor (TGCT), laryngeal squamous cell carcinoma 
(LSCC), lung adenocarcinoma (LA), pancreatic adenocarcinoma (PA), 
gastric cancer (GC), non-small cell lung cancer (NSCLC), breast cancer 
(BC), prostate cancer (PC), melanoma (MM), osteosarcoma (OS), 
bladder cancer (BlC), glioblastoma (GBM) and glioma (GM). Either in-
duction or suppression of proliferation, migration, invasion, apoptosis, 
and cell-cycle arrest are distinct roles of miR-1297 in various cancers. 
Moreover, its expression level is frequently measured to be lower in 
cancerous tissues than the normal adjacent tissues, suggesting that miR- 
1297 is a tumor suppressor. On the contrary, in some cancers miR-1297 
acts as an oncogene, meaning that the function of miR-1297 in human 
neoplasms is cancer-type specific. MiR-1297 plays a dual role by tar-
geting different genes, as summarized in Table 2. In several cancers, 
tumorigenesis occurs following the action of Long non-coding RNAs 
(lncRNAs) or Circular RNAs (CircRNAs), which targets miR-1297 and 
acts as a competitive endogenous RNA (ceRNA), the so-called sponge 
effect (Table 3). Moreover, Fig. 2 summarizes the interaction of miR- 
1297 with its target genes, lncRNAs, and CircRNAs as well as down-
stream signalling pathway. 
4. MiR-1297 and nervous system cancers 
Primary brain and central nervous system (CNS) cancers occur in 
both children and adults which are diagnosed in all anatomical regions 
of the CNS. These malignancies mainly affect the brain (>90%), and the 
Fig. 1. The hairpin structure of pre-miR-1297 and the sequence of mature miR-1297. The miR-1297 gene is transcribed into a precursor (pre-miR-1297) with 77 
nucleotides in the nucleus, and then transferred to the cytoplasm by Exportin-5 for further processing to develop into mature miR-1297 with 17 nucleotides. The 
sequence of mature miR-1297 is colored in red. The arrow indicates the orientations from 5′ to 3′. The codes of miR-1297 were extracted from miRBase. 
S. Alizadeh-Fanalou et al.                                                                                                                                                                                                                     
Biomedicine & Pharmacotherapy 141 (2021) 111863
3
Table 1 
The roles of miR-1297 in health (physiology) and diseases (excluding cancer).  
Types of disease 
and health 
conditions 
Aim of study Role of miR-1297 References 
Myocardial 
fibrosis 
Investigation of the 
role and underlying 
mechanisms of miR- 
1297 in myocardial 




ULK1, as the target 
gene was up-regulated 
in the MF model. The 
protein levels of 





overexpression of miR- 
1297 or the 
knockdown of ULK1. 
More importantly, the 
regulatory effect of 
miR-1297 on MF was 




ULK1 overcame MF. 
[41] 
Osteoporosis Investigation of the 









the osteogenesis of 
hBMSCs by 
overexpression of 





OSX, ALP, OCN, OPN, 
and COL1A1) 
[42] 
Panic disorder Investigation of the 
altered expression of 
miR-1297 in the serum 
of panic disorder 
patient 
MiR-1297 expression 
was up-regulated in 
the patients, 
suggesting that it can 
potentially be 








in the serum of HF 
patients using mining 
strategy 
COX-2 and miR- 
4649–3p were 
significantly 
upregulated, and miR- 
1297 was remarkably 
downregulated, 
suggesting that both 
miRNAs could be 
utilized as novel 
biomarkers for non- 
ischemic HF patients. 
[44] 
Glaucoma Investigation of a 
precise function of the 
lncRNA‑associated 
ceRNA network using 
downloaded data from 





cell (HTMC) samples 
under oxidative stress 
Demonstration of 
differential expression 
profiles of 24 lncRNAs 
confirmed the 
upregulation of 19 
lncRNAs and 
downregulation of 5 
lncRNAs. Also, 24 
miRNAs (including 
miR-1297) and 40 
mRNAs were 
constructed as a 
lncRNA‑associated 
ceRNA network in 
HTMCs under 
oxidative stress. 
Finally, an innovative 
pathological 
mechanism or a 
possible therapeutic 
[45]  
Table 1 (continued ) 
purpose for glaucoma 
was identified. 
Bone formation Investigation of the 
relation between 
miRNAs and mRNA 






target genes and 
proteins such as 
WDR33, HSPH1, 
ERBB3, RIF1, IKBKB, 
CREB1, FGF2, and 





4328, 224–5p related 
to tension force- 
induced bone 
formation in PDLC 
confirmed valuable 
evidence to advance 
investigation of the 
regulatory network in 
this complex process 
[46] 




Investigation of the 
role of miR-1297 in 
the evolution of NSCs 
Upregulation of miR- 






mir-1297 leaded to 
decreased and 
increased expression 
of GFAP and β-tubulin 
III, respectively. 
Therefore, mir-1297 










profile alterations in 
UA patients utilizing 
gene-chip analysis 
MiR-1297 was up- 
regulated, suggesting 
a possible role as a 
biomarker for the 
diagnosis and 





Investigation of the 
expression levels of 
miRNAs in the serum 
of SAH patients and 
their relationships 
with the severity and 
clinical outcome of 
SAH 
miRNAs 1297, 
502–5p, 4320 were 
remarkably 
upregulated, and miR- 
4320 was noticed to be 
a potential diagnostic 
biomarker of SAH. 
However, miR-502–5p 
and miR-1297 were 
identified to be 
biomarkers of the 
diagnosis, severity, 





Investigation of the 
role of mir-1297 in D- 
Glucose-treated HK-2 
cell lines (used to 
mimic DN status) 
MiR-1297 enhanced 
cell proliferation and 
suppressed 
inflammation by 
targeting the COL1A2 
gene. Furthermore, 
knockdown of 
COL1A2 improved the 
protecting effects of 
miR-1297 on high 
glucose-stimulated 
HK-2 cells. Therefore, 
mir-1297 can be 
considered as a novel 
therapeutic approach 




Investigation of serum 
expression of miR- 
Different levels of mir- 
1297 expression of at 
[5] 
(continued on next page) 
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rest affect the meninges, spinal cord, and cranial nerves [54]. The 
incident cases of CNS tumors were reported to be 330,000 in 2016, and 
227,000 deaths were recorded, worldwide. Between 1990 and 2016, the 
age-standardized incidence rates of CNS malignancy expanded globally 
by 17.3% [54]. Therefore, the molecular basis of GM should urgently be 
elucidated which pave the way for investigation of innovative targets to 
generate novel therapeutic and diagnostic approaches for this 
life-threatening illness. Dysregulation of many miRNAs have been re-
ported in GM. Accordingly, Wang et al. in 2016 for the first time re-
ported that miR-1297 takes part in gliomagenesis by directly targeting 
and downregulating the expression of the high mobility group protein 
A1 (HMGA1) in GM cells. HMGA1 is usually intensely expressed during 
development and plays key roles in organizing normal cell proliferation, 
embryonic cell growth, and cell differentiation. Although the expression 
of HMGA family proteins in adult tissues is scarcely detectable, HMGA1 
expression is stimulated in various types of human tumors. Moreover, it 
has been proven that HMGA1 is involved in cancer progression and can 
be considered as a biomarker for tumor diagnosis and remedy. The 
studies conducted by Wang et al. confirmed that miR-1297 expression 
levels in tissue specimens and cell lines were remarkably down-
regulated, and HMGA1 gene expression was elevated. Furthermore, they 
showed that ectopic overexpression of miR-1297 in vitro reduces cell 
viability and proliferation as well as inhibits the growth of xenograft 
tumor in vivo through downregulation of HMGA1 [55]. One of the 
hallmarks of cancer cells is reprogramming glucose metabolism and the 
consequent high glycolysis rate, also known as the Warburg effect. As a 
member of the karyopherin family, karyopherin subunit alpha 2 
(KPNA2) is involved in the transportation of macromolecules such as 
transcription factors into the nucleus and correlated with metabolism 
reprogramming. KPNA2 can be considered a fundamental regulator of 
glycolysis in many cancers, including GBM. In this regard, Wang et al. in 
2020 exhibited that KPNA2 is notably up-regulated both in tissue sam-
ples of GBM patients and cell lines, resulting in improved glycolytic 
metabolism. As evidenced, lactate levels, glucose uptake, and extracel-
lular acidification rate (ECAR) as an indicator of the Warburg effect and 
oxygen consumption rate (OCR) as a reflector of mitochondrial respi-
ration dramatically were promoted. Also, it was reported that KPNA2 
enhanced glycolytic metabolism via activation of c-Myc signaling. Their 
study revealed that the expression level of miR-1297 both in tissue 
specimens and cell lines was considerably downregulated and correlated 
with the poor prognosis of the patients. However, forced overexpression 
of miR-1297 in cell lines downregulated KPNA2 to control expression of 
crucial genes involved in glycolysis and subsequently inhibited cell 
proliferation and glucose metabolism in GBM. As evidenced, ectopic 
overexpression of miR‑1297 decreased enzymatic activities of critical 
enzymes, including PFK, PKM, and HK2 in the glycolytic pathway [56, 
57]. Recently, the critical roles of CircRNAs in tumorigenesis, metas-
tasis, invasion, malignant transformation, signal transduction, and 
angiogenesis were explained. Oncogenic functions of hsa_circ_0030018 
in promotion of tumorigenesis and invasiveness in numerous human 
tumors have already been confirmed [58,59]. With this aspect, Song 
et al. in 2021 revealed high expression of hsa_circ_0030018 and low 
expression of miR-1297 in GM tissue and cell lines. They found that 
miR-1297 is a direct target of hsa_circ_0030018. Their results also 
demonstrated that hsa_circ_0030018 silencing or forced overexpression 
of miR-1297 might decrease cell proliferation, metastasis as well as 
promote apoptosis, and cycle arrest in GM cell lines via targeting 
Ras-Related Protein Rab-21 (RAB21). Besides, knockdown of hsa_-
circ_0030018 repressed tumor progression in vivo. Therefore, hsa_-
circ_0030018 silencing might undermine its anti-tumor functions by 
mediating the miR-1297/RAB21 signaling pathways via upregulation of 
miR-1297 [58]. LncRNAs are considered to be important molecules to 
manage CNS tumors, especially GM [60]. LncRNAs with longer than 
200nt in length consist of the principal part of human RNA and exert 
functions via regulation of gene expression at both transcriptional and 
post-transcriptional levels through interactions between DNA, RNA, and 
proteins. Recently, dysregulated expression of lncRNAs in multiple 
human neoplasms and their regulatory roles in cellular and biological 
function were proved [61–63]. In this regard, Liu et al. in 2021 estab-
lished the oncogenic capacities of lncRNA DLGAP1 antisense RNA 1 
Table 1 (continued ) 
hemorrhage 
(aSAH) 
1297 over multiple 
periods in aSAH 
patients 




correlation of miR- 
1297 concentrations 
in serum with severity 
in aSAH was 
confirmed. Therefore, 
serum levels of miR- 
1297 can be 
considered as a 
prognosis biomarker 
for aSAH patients. 
Neurotoxicity Investigation of the 
role of miR-1297 in 
sevoflurane-induced 
neurotoxicity 
Up-regulation of miR- 
1297 was confirmed in 
sevoflurane-exposed 
mice. Overexpression 
of miR-1297 in the in 
vitro model reduced 
cell proliferation, but 
increased apoptosis, 
and LDH activity. 
Further experiments 















Investigation of the 
role of lipotoxic 
exosomal miR-1297 in 
MAFLD 
Up-regulation of miR- 




overexpression of miR- 
1297 in exosomes 
derived from lipotoxic 
hepatocytes 
stimulated the 
progression of liver 
fibrosis by activation 
and proliferation of 
hepatic stellate cells 
through the 






Investigation of the 
lncRNA-miRNA- 
mRNA (ceRNA) 








that influenced the 
mentioned network, 
such as HCP5–1297- 
ADM in detached 
human retinas 
consisting of 9 PVR- 
specific lncRNAs, as 
well as 27 miRNAs and 
73 mRNAs were 
demonstrated. These 
results could enhance 
understanding of the 
pathogenesis of 
human retinal 
detachment with PVR 
and provide new 
lncRNAs as possible 
therapeutic objectives. 
[53]  
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Table 2 
Target genes of miRNA-1297 responsible for its tumor suppressive or oncogenic properties in different cancers.  




tissue Cell lines 
GM HMGA1 6p21.31 NHA U251, U87, A172, LN 340, 
TJ905, U373 
10p Induced apoptosis and inhibited 
cell proliferation 
[55] 
RAB21 12q21.17 c c c Induced apoptosis and cycle 
arrest; inhibited cell proliferation 
and metastasis 
[58] 
EZH2 7q36.1 NHA U251, T98G, U87 and 
LN229 
24a Inhibited cell proliferation, 
migration, and invasion 
[60] 
GBM KPNA2 17q24.2 N/A U87MG, U138MG 49a Inhibited cell proliferation and 
glucose metabolism 
[56] 
LSCC PTEN 10q23.31 N/A Hep-2 10p Inhibited cell viability, migration, 
and tumorigenesis 
[65] 
NSCLC Skp2 5p13.2 N/A A549, NCI-H460 16p Inhibited cell proliferation [66] 
PTEN 10q23.31 
AKT 14q32.33 
LA TRIB2 2p24.3 N/A A549, LTEP-a-2 Not-mentioned Inhibited cell viability and 
induced apoptosis 
[67] 
PA MTDH 8q22.1 N/A PANC-1, BxPC-3 22p Inhibited cell proliferation, 
migration, and induced apoptosis 
[124] 
OS PFKFB2 1q32.1 hFOB1.19 MNNG-HOS, U-2OS Saos-2 
and MG63 
40a Inhibited cell proliferation, 
metastasis, and aerobic glycolysis; 
Induced apoptosis 
[125] 
MM PTEN 10q23.31 HaCaT WM-115, Malme-3 M, MSK- 
MEL-1 and A375 
63p Inhibited cell proliferation, 
migration, and EMT 
[126] 
TGCT PTEN 10q23.31 N/A NCCIT 33p Inhibited cell growth [102] 
TGCT PTEN 10q23.31 N/A NCCIT Not-mentioned Inhibited cell proliferation [101]  
TET3 2p13.1 MCF-10A MCF-7, SW626, HCC1937 20p Inhibited cell proliferation, 
migration, invasion, and EMT 
[73] 
BC PTEN 10q23.31 MCF-10A T47-D, MCF-7, MDA-MD- 
231, MDA-MB-453, BT-549 
116p Inhibited cell cycle and induced 
apoptosis 
[77]  
TAZ 3q25.1 MCF-10 A MDA-MB-231, MCF-7, and 
MDA-MB-468 
Not-mentioned Inhibited cell proliferation, cell 
cycle, and migration 
[74]  
FA2H 16q23.1 N/A MDA-MB-231 Not-mentioned Inhibited EMT [81] 
PC AEG-1 8q22.1 RWPE-1 PC-3, LNCaP, DU-145 and 
22RV-1 
20p Inhibited cell proliferation and 
invasion 
[130] 
PTEN 10q23.31 RWPE‑2 
(CRL‑11610) 
DU145 (HTB‑81), VCaP 
(CRL‑2876), PC‑3 
(CRL‑1435) and LNCaP 
(CRL‑1740) 
90p Inhibited cell migration and 
invasion 
[128] 
CC AEG-1 8q22.1 H8 C33A, HeLa, CaSki and SiHa 117p Inhibited cell migration, invasion 
and EMT 
[98]  
PTENd 10q23.31 N/A HeLa Not-mentioned Inhibited cell proliferation and 
induced apoptosis 
[100]  
PTENd 10q23.31 N/A SSC-4 16p Inhibited cell proliferation [121] 
OSCC GSK3β 3q13.33 SCC-090 UM-SCC6 Not-mentioned Inhibited apoptosis and induced 
cell proliferation 
[122] 
BlC EphA2 1p36.13 N/A T24 Not-mentioned Inhibited cell proliferation and 
induced apoptosis 
[103]  
HMGA2 12q14.3 N/A HepG2 and SMMC7721 Not-mentioned Inhibited cell proliferation and 
migration; Induced apoptosis 
[87]  
ROCK1 18q11.1 LO2 and 
HEK293 
MHCC97H, HCCLM3, SK- 
HEP-1, Hep3B, and Huh7 
60p Inhibited cell proliferation, 
migration, and invasion 
[91] 
HCC EZH2 7q36.1 N/A Hep3B and HepG2 35p Inhibited cell proliferation and 
induced apoptosis 
[90]  
RB1 13q14.2 N/A HepG2 496p Inhibited cell proliferation [92]  
MAT2A 2p11.2 N/A Huh7, HCC-LM3, SK-Hep-1, 
and Hep3B 
50p DNA Hypomethylation [93]  
CCND2 12p13.32 293 T SW480 32p Inhibited cell proliferation and 
metastasis 
[108] 
CRC COX2 1q31.1 N/A LOVO, HCT116, SW480, 
SW-620, HT29 and HCT8 
20p Inhibited growth, migration, and 
invasion of cells; repressed 
tumorigenesis in vivo 
[84]  
xCT 4q28.3 119p Inhibited cell proliferation [89] 
(continued on next page) 
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(DLGAP1-AS1) and enhancer of zeste homolog 2 (EZH2) in GM pro-
gression as well as the tumor-suppressive function of miR-1297 in 
repressing GM. According to their results, lncRNA- DLGAP1-AS1 and 
EZH2 were up-regulated in GM tissue and cell lines; however, the 
expression of miR-1297 was down-regulated. EZH2 as a direct target 
gene of miR-1297 caused histone methylation and gene silencing via 
post-translational histone alterations, but DLGAP1-AS1 by sponging 
miR-1297 accelerated the expression of EZH2 and promoted invasion, 
migration, and proliferation in GM cell lines. Furthermore, they noticed 
that silencing DLGAP1-AS1 not only suppressed GM progression but also 
restrained tumorigenicity in vivo [60]. Taking together, the 
above-mentioned studies demonstrate that miR-1297 acts as a tumor 
suppressor in CNS malignancies and can be considered as a novel 
diagnostic and therapeutic target. 
5. MiR-1297 and respiratory system cancers 
Respiratory diseases are consistently considered to be the main 
threat to public health and are listed among the fatal diseases in 
developed countries [64]. Of significant importance, lung cancer with 
the highest morbidity and mortality worldwide is the most frequent 
malignant neoplasm. Small cell lung cancer (SCLC) and NSCLC are two 
main types of lung cancer. It has been claimed that respiratory malig-
nancies in the United States were responsible for 147,510 deaths in 2019 
[1]. With this aspect, rapid diagnosis and timely treatment of the pa-
tients are essential for improving life and survival rate. 
According to available evidence, miR-1297 is implicated in both 
upper and lower respiratory tract neoplasms. In this regard, Li et al. in 
2019 noticed that the expression of mir-1297 was high in LSCC in 
cancerous cell lines and clinical tissue samples compared to the adjacent 
non-neoplastic tissues, suggesting that it might act as an oncogene by 
regulating phosphatase and tensin homolog deleted on chromosome ten 
(PTEN) related signaling pathway. Additional experiments validated 
that high expression levels of miR-1297 through downregulation of 
PTEN can promote cancer cell proliferation, migration, and tumori-
genesis. Numerous studies have proved that PTEN as a tumor suppressor 
gene is downregulated in various primary human cancers, and its ac-
tivity notably declines via mutations or promoter methylation. There-
fore, the lack of PTEN function results in the accumulation of PIP3, 
stimulating the activation of its downstream effectors, particularly 
Table 2 (continued ) 
CCD-112Con 
and CCD 841 
LoVo, SW 620, SW 1116, SW 
480 and RKO 
CDC6 17q21.2 GES-1 SGC-7901, MKN-45, and 
BGC-823 
38p, 43a Inhibited cell proliferation and 
colony formation; Induced 
apoptosis 
[114]  
EZH2 7q36.1 N/A N/A 85p Inhibited cell proliferation and 
invasion 
[113] 
GC HMGB2 4q34.1 GES-1 MKN45, MKN28, BGC-823, 
and SGC-7901 
78p Inhibited cell proliferation, 
invasion, and metastasis 
[115]  
CREB1 2q33.3  MKN-45 and SGC-7901 62p Inhibited cell growth in vitro and 
in vivo 
[85]  
E2F3 6p22.3 GES-1 MKN74 and HGC27) 51p Inhibited cell proliferation, 
invasion, migration; Induced 
apoptosis and cell cycle arrest 
[131] 
Notes: 
aTissue specimens are not in pairs. The genes’ names were abbreviated according to GenBank. 
bafter treatment with miRNA mimic or inhibitor; knockdown of target gene or lncRNA and circRNA. 
cLack of access to the full-text article to complete the required information. 
dPTEN is recognized as a tumor suppressor gene, evidenced by down-regulation in various tumors; however, it displays oncogenic roles in CC and OSCC. Therefore, 
these inconsistencies need further investigation in future studies. 
Table 3 
Oncogenic circ RNA and lncRNA act as ceRNA for miR-1297 in different cancers.  




LncRNA-SNHG6 HCC N/A Huh7, HCC-LM3, SK-Hep-1, and 
Hep3B 
50p Induced cell proliferation and invasion;Inhibited 
apoptosis 
[93] 
Hsa_circ_101141  LO2 and 
HEK293 
MHCC97H, HCCLM3, SK-HEP-1, 
Hep3B, and Huh7 
60p Induced cell proliferation, migration, and invasion [91] 
LncRNA-GAS5 OSCC SCC-090 UM-SCC6 Not-mentioned Induced apoptosis and inhibited cell proliferation [122] 
CCA HIBEC RBE, CCLP1, HuCCT1 and HCCC- 
9810 
59a Induced cell proliferation and invasion [63] 
Hsa_circ_001418 BlC N/A T24 Not-mentioned Induced cell proliferation and inhibited apoptosis [103] 
Hsa_circ_PGPEP1  GES-1 MKN74 and HGC27) 51p Induced cell proliferation, invasiveness and 
migration; Inhibited apoptosis 
[131] 
LncRNA-MALAT1 GC GES-1 MKN45, MKN28, BGC-823, and 
SGC-7901 





N/A N/A 85p Induced cell proliferation and invasiveness [113] 
Hsa_circ_0091074 BC MCF-10 A MDA-MB-231, MCF-7, and MDA- 
MB-468 
Not-mentioned Induced cell proliferation and invasiveness [74] 
Hsa_circ_0030018 GM b b b Inhibited apoptosis and cell cycle arrest; Induced 




NHA U251, T98G, U87 and LN229 24a Induced cell proliferation, migration and invasion [60] 
LncRNA-Meg3 TGCT N/A NCCIT 33p Inhibited cell growth [102] 
Notes: a Tissue specimens are not in pairs 
b Lack of access to the full-text article to complete the required information 
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PDK1, Akt/PKB, and Rac1/cdc42 leading to cancer progression. Addi-
tionally, they showed that downregulation of miR-1297 inhibits cancer 
progression in vitro and attenuates tumorigenesis in vivo [65]. Consis-
tent with the previous study, Bu and Lou also in 2017 determined that 
miR-1297 might be oncogene by regulating the PTEN/Akt/Skp2 
signaling pathway in NSCLC. Their study confirmed the downregulation 
of PTEN in NSCLC samples compared to the paired normal tissues. They 
also observed that S-phase kinase-associated protein 2 (Skp2) in NSCLC 
tissues and cell lines were conversely correlated with the expression 
levels of PTEN. As an essential enzyme, Skp2 plays a central role in the 
process of cell cycle development, signal transduction, and transcription 
through the ubiquitination and consequent proteasomal degradation of 
target proteins. Overexpression of Skp2 in multiple human malignancies 
was described, and it has been demonstrated that Spk2 induces cancer 
cell expansion and progression. Also, Spk2 in PC cells is correlated with 
chemotherapeutic drug resistance. Furthermore, they showed that 
transfection of miR-1297 mimic in NSCLC cell lines via downregulation 
of PTEN and upregulation of Skp2 increases cell proliferation. On the 
other side, the miR-1297 inhibitor could repress cancer progression 
through reversing the expressions of PTEN and Skp2 via enhancing 
levels of phosphorylation of Akt. Therefore, in NSCLC patients, PTEN 
and Spk2 can be considered as potential targets for gene therapy [66]. 
Contrary to the above-discussed studies, another research disclosed that 
miR-1297 and miR-511 might be a tumor suppressor gene via regulating 
the tribbles pseudokinase 2/ CCAAT/ enhancer-binding protein alpha 
(TRIB2-C/EBPα) signaling pathway. As an inhibitor of mitosis, Tribbles 
participate in the regulation of cell proliferation, migration, and 
morphogenesis during the development. It has been reported trib1, 
trib2, and trib3 genes are responsible for encoding tribbles homologs in 
mammals. Substantial evidence also illustrated that TRIB2 has an 
oncogenic role in various human neoplasms, for instance, acute myeloid 
leukemia (AML) via inhibiting the downstream factor of TRIB2 
(C/EBPα). Tribbles proteins enhance the degradation of C/EBPα and 
C/EBPβ transcription factors via promotion of ubiquitin-dependent 
degradation pathway. TRIB2 requires an intact C-terminal constitutive 
photomorphogenesis 1(COP1)-binding site to deteriorate C/EBPα. 
TRIB2 via binding to the C/EBPα blocks its binding to DNA; thus, the 
transcriptional activity of C/EBPα is lost. Zhang et al. in 2017 recorded 
TRIB2 upregulation and downregulations of miR-1297 and miR-511 in 
human LA compared to the control tissue samples. These results may 
support a potential oncogenic function for TRIB2 and suppressor role for 
miR-1297 and miR-511 in the pathological alterations of LA. They also 
demonstrated that transfection with miR-1297 and miR-511 mimics 
could inhibit cell proliferation in vitro and in vivo by suppressing TRIB2 
and further enhancing C/EBPα expression. Also, the findings confirmed 
that high levels of miR-1297 and miR-511 expression could remarkably 
enhance the apoptotic rate [67]. In summary, although these findings 
are remarkable and exciting, further studies should be conducted to 
clarify the specific roles of miR-1297 as a tumor suppressor gene or 
oncogene in respiratory system cancers. Furthermore, its association 
with ceRNA and lncRNA in progression or suppression of related tumors 
should be further investigated. 
Fig. 2. MiR-1297 regulates tumorigenesis by targeting different genes and downstream signaling pathways, as illustrated [55,56,58,60,63,65–67,73,74,77,81,84,85, 
87–93,98,100–103,108,113–115,121,122,124–126,128,130,131]. For example, miR-1297 represses tumorigenesis by suppressing the expression of the HMGB2 
gene, but lncRNA-MALAT1 reverses the anti-tumor effect of miR-1297. On the other hand, miR-1297 promotes tumorigenesis by suppressing the expression of the 
GSK3β gene. Propofol stimulates expression of the FoxO1 transcription factor, then FoxO1 attaches to the promoter of GAS5, promoting its transcription; subse-
quently, GAS5 sponged the miR-1297 and caused cancer progression. miR-1297 directly inhibits the expression of the AEG-1 gene then indirectly suppresses C-Myc 
and Cyclin D1 as components of the Wnt signaling pathway, causing tumor suppression. miR-1297 could directly bind to the FUS 3′-UTR mRNA as an RNA binding 
protein (RBP) and inhibits its expression. Therefore, MAT1A mRNA nucleocytoplasmic shuttling was activated, causing promoted MAT1A mRNA and protein in the 
cytoplasm, subsequently significantly increases SAMe. Also, miR-1297 suppresses MAT2A expression and increases SAMe concentration. Thus, overall, cancer 
suppresses via instability genome. However, SNHG6 reverses the anti-tumor effect of miR-1297. HOXA11-AS may function as a scaffold and directly bind with EZH2 
and LSD1 at their 5′ and 3′ regions, respectively. EZH2 and LSD1 inhibit PRSS8 and KLF2 as a novel tumor suppressor gene through methylation modification, 
causing tumor progression. In this process, E2F1 stimulated HOXA11-AS transcription. 
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6. MiR-1297 and breast cancer 
BC is one of the most common malignancies in women worldwide 
and the leading cause of 15% of cancer deaths in women [68]. According 
to GLOBOCAN 2020 estimates, female breast cancer has surpassed lung 
cancer as the most commonly diagnosed cancer, with an estimated 2.3 
million new cases [69]. In the recent decades, the mortality rate because 
of BC has decreased dramatically due to effective advances in treatment 
and diagnosis. However, the prognostic predictors and precise mecha-
nisms involved in BC progression have not yet been well understood 
[70]. Therefore, an accurate understanding of BC’s molecular mecha-
nisms is essential to identify more ideal biomarkers and new therapies. 
MiRNAs are one of the molecular factors involved in the development of 
BC. More specifically, miRNAs have been shown to act as a regulatory 
factor in BC’s molecular mechanisms [71,72]. To date, several articles 
have been published on the role of miR-1297 in the pathogenesis of BC 
[11,73–77]. These studies indicate that miR-1297 takes part in the 
pathogenesis of BC, through regulation of proliferation, migration, in-
vasion, and apoptosis in BC cells. Nevertheless, contradictory results 
have been reported regarding whether miR-1297 is a tumor suppressor 
or an oncogene in BC. 
The first study by Liu et al. in 2017 investigated the effect of miR- 
1297 on BC cell growth to identify related signaling pathways [77]. In 
BC clinical tissue specimens and cell lines, it was proved that miR-1297 
expression was elevated. Overexpression of miR-1297 was also found to 
induce cell proliferation and inhibit apoptosis. This study stated that 
PTEN is a direct target of miR-1297 and its expression level is reduced in 
BC cell line and tissue samples. Thus, miR-1297 by suppressing PTEN 
increases cell proliferation and cell cycle as well as inhibits apoptosis via 
activation of PI3K/AKT signaling. This study also revealed that 
miR-1297 induces cyclin D1 and inhibits p27 via the PTEN/PI3K/AKT 
pathway [77]. According to previous studies, activation of the 
PI3K/AKT pathway leads to development and progression of BC through 
induction of cell proliferation and migration and inhibition of apoptosis 
[78,79]. The authors concluded that miR-1297 is an oncogene in BC, 
and PTEN has a tumor-suppressing effect by inhibiting the PI3K/AKT 
pathway [77]. Another study was conducted in 2019 by Xueyun et al. to 
evaluate the effect of miR-1297 on BC cells and elucidate its molecular 
mechanism [73]. The results showed that miR-1297 expression levels in 
BC tissues and MCF-7 cells increased significantly which were associated 
with the activation of malignant biological behaviors, including pro-
moted proliferation, invasion, migration, and epithelial-mesenchymal 
transition (EMT) of cells, through down-regulation of TET3, as a direct 
target. The decrease in miR-1297 also reversed cellular behaviors [73]. 
The family of ten-eleven translocation (TET), as DNA demethylases, are 
tumor suppressors required to maintain genomic instability. According 
to the available evidence, TET3 acts as an oncogene or tumor inhibitor in 
ovarian cancer [80]. TET affects tumorigenesis through increasing 
chemotherapy sensitivity. Therefore, Xueyun and colleagues concluded 
that miR-1297, as an oncogene, by inhibiting the expression of TET3, 
leads to the activation of malignant behaviors in BC tissues and MCF-7 
cells [73]. To have a better insight into the molecular mechanisms of 
BC tumorigenesis, Li et al. (2020) investigated the role of miR-1297 in 
BC cell lines and tissues samples [81]. The results showed that miR-1297 
inhibitor significantly reduced cell proliferation, suppressed EMT, and 
increased apoptosis in-vitro. Moreover, the elevation of FA2H (fatty acid 
2-hydroxylase) expression also inhibits cell proliferation and induces 
apoptosis. The bioinformatics analysis and different experiments 
showed that miR-1297 targets FA2H directly [81]. Several studies have 
examined the effect of FA2H on tumorigenesis [82,83]. It was reported 
that FA2H is involved in several cellular signaling pathways, such as the 
mTOR and AMPK [82]. The expression level of FA2H decreases in BC 
and GC tissues [82,83]. Additionally, FA2H can reduce drug resistance 
in tumor cells. Therefore, it was suggested that FA2H could play a role in 
inducing the drug’s sensitivity by modulating endocytosis and excretion 
of drugs through cell membranes. Based on Li et al. investigation, it can 
be concluded that miR-1297, as an oncogene, increases cell proliferation 
by inhibiting the expression of FA2H (as a tumor suppressor) in BC [81]. 
On the other hand, some studies have reported that miR-1297 is a tumor 
suppressor because of its reduced expression in BC cells [74,75]. For 
example, Hu et al. in 2020 found that hsa_circ_0091074 expression 
levels increase in BC cells which acts as an endogenous sponge for 
miR-1297 leading to reduction of miR-1297 expression. It was also 
found that the TAZ as a direct target of miR-1297, is overexpressed in BC 
following action of hsa_circ_0091074. TAZ is a critical downstream 
factor in the Hippo signaling pathway, which plays an essential function 
in modulating cell proliferation, tissue growth, and regeneration. It was 
shown that an increase in the TAZ is directly related to the invasive type 
of BC and the induction of EMT cells [74]. In 2019, Mosapour et al. 
reported that miR-1297 could be a tumor suppressor in BC cells [75]. It 
was shown that the expression level of miR-1297 in malignant breast 
tumors is significantly lower than in benign breast tumor samples [75]. 
The results are consistent with several other studies in which miR-1297 
expression was downregulated in malignant tumors such as pancreas, 
lung, gastric, and colon cancers [84,85]. Next, they examined the rela-
tionship between miR-1297 and very-low-density lipoprotein (VLDL) 
receptor in benign and malignant breast tumors because it was predicted 
that VLDL receptor is a direct target for miR-1297. However, the ex-
periments showed that expression of VLDL receptor and miR-1297 in 
malignant tumors are declined. The VLDL receptor is a multifunctional 
receptor and can be involved in developing tumors by regulating the 
proliferation and apoptosis of BC cells [76]. In brief, the 
above-mentioned studies illustrate that miR-1297 plays a crucial role in 
tumor-suppressing or progressing of BC, suggesting that miR-1297 
might be an important target for both prognosis and treatment of BC. 
However, the specific role of miR-1297 in BC should be illuminated with 
the investigation of massive genes and signaling pathways which can be 
affected by miR-1297 or investigation of lncRNAs and circRNAs which 
can modify miR-1297 expression level. 
7. MiR-1297 and hepatocellular carcinoma 
Today, HCC is recognized as the most common type of liver cancer 
and the fifth most frequently diagnosed cancer, globally [86,87]. Also, it 
is the third leading cause of cancer death [86]. According to the litera-
ture, the incidence of HCC is gradually increasing in developed and 
developing countries [87]. Despite significant advances in conventional 
therapies, the average survival for HCC patients is about nine months, 
excluding liver transplantation [87]. Liver transplantation is the gold 
standard treatment for liver cancer, but it cannot always be conducted 
everywhere [86]. 
Therefore, understanding the molecular mechanisms in the process 
of tumorigeneses, such as proliferation, migration, and cellular 
apoptosis, is essential for the development of new treatments for HCC 
[87]. MiRNAs are one of the influential factors in signaling pathways 
and miR-1297 plays vital roles in various human cancer pathogenesis 
[88,89]. Recently, the role of miR-1297 in the pathogenesis of HCC was 
deeply investigated [86,87,90–93]. However, conflicting results have 
been reported regarding the oncogene or tumor suppressor role of 
miR-1297. Although, each of these articles has reported the effect of 
miR-1297 on separate signaling pathways, the common point is that all 
of these signaling pathways are involved in tumorigenesis, including 
proliferation, migration, and apoptosis of cells. Therefore, it can be said 
that miR-1297 is a molecular regulator in the signaling pathways of 
HCC, but the signaling pathways and the obtained results are slightly 
controversial. In this regard, Liu et al. in 2015 investigated the role of 
miR-1297 in regulating the proliferation and apoptosis of HCC cell lines 
by targeting the HMGA2 [87]. The results showed that the HMGA2 is a 
direct target of miR-1297. The overexpression of miR-1297 by sup-
pressing HMGA2 led to significant inhibition of cell proliferation and 
migration, as well as induction of apoptosis in-vitro. Therefore, 
miR-1297 was introduced as a tumor suppressor and the HMGA2 as an 
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oncogene. In general, HMGA2 is active in several malignancies (such as 
cancers of lung, breast, and pancreas), and its inhibition by miR-1297 
can contribute to inhibition of tumor growth and metastasis and in-
duction of apoptosis [87,94]. Another study conducted by Liu et al. in 
2015 on HCC examined the effect of miR-1297 on proliferation and 
apoptosis of cells by directly targeting the EZH2 (histone-lysine 
N-methyltransferase) [90]. The results showed that the miR-1297 
expression was significantly lower in HCC cells, and inversely, the 
EZH2 expression was elevated. The overexpression of miR-1297 led to a 
significant reduction in cell proliferation and induction of apoptosis in 
HCC cells. The knockdown of the EZH2 also led to the recording of the 
same results [90]. Enzyme EZH2 is involved in maintaining the tran-
scriptional suppression of many genes by DNA methylation. Abnormal 
expression of EZH2 has been reported in lymphoma, PC, and HCC, 
indicating that it plays an important role in tumorigenesis. Therefore, 
miR-1297, by inhibiting the EZH2, could be an ideal treatment for HCC 
[90,95]. A study conducted by Liu et al. in 2016 investigated the role of 
miR-1297 in the proliferation of liver cancer cells by targeting the RB1 
(retinoblastoma protein1) [92]. The results showed that overexpression 
of miR-1297, as an oncogene, leads to an increase in cell proliferation, 
and miR-1297 inhibitor leads to inhibition of cell proliferation. Also, 
miR-1297 increased cell proliferation by suppressing the RB1 expres-
sion. It has been proven that RB1 is a tumor suppressor and through 
negative regulation of the cell cycle, inhibits cell proliferation in several 
cancers, such as liver cancer [92,96]. In 2018, Guo et al. studied the 
effect of miR-1297 and lncRNA SNHG6 on HCC cells [93,129]. Pre-
liminary results showed high levels of lncRNA SNHG6 in HCC cells and 
decreased expression levels of miR-1297. Also, the MAT2A (methionine 
adenosyltransferase-A2) was identified as a direct target for miR-1297. 
MATs are essential enzymes for the mediate formation of SAMe 
(S-adenosylmethionine) in mammalian cells. MATA1 has a high con-
centration in quiescent liver cells and leads to an increase in the SAMe. 
Conversely, MATA1 in cancer cells is decreased, and the level of MAT2A 
enzyme is increased. In HCC cells, the lncRNA SNHG6 increases the level 
of the MAT2A by sponging miR-1297. As a result, the lncRNA SNHG6, 
with an increase in MAT2A, leads to a decrease in the SAMe, resulting in 
hypomethylation of HCC cells [93]. In 2020, Zhang et al. examined the 
effect of circRNA human_circ_101141 on HCC cell’s tumorigenesis by 
regulating the miR-1297/ROCK1 pathway [91]. Recently, it has been 
reported that circRNAs, as a new class of non-coding RNAs, are involved 
in cell development and function by regulating gene expression during 
transcriptional and post-transcriptional phases. However, their role in 
the pathogenesis of HCC is still unclear. The results of this study showed 
that the ROCK1 and circ_101141 expressions are up-regulated in HCC 
cells. The downregulation of the circ_101141 was accompanied by in-
hibition of growth, migration, and invasion of cells. miR-1297 inhibits 
growth, migration, and invasion of cells by directly targeting ROCK1 in 
normal cells. However, circ_101141 increases ROCK1 in HCC cells 
through sponging miR-1297. Thus, circ_101141 increases the growth, 
proliferation, and invasion of cancer cells by increasing the ROCK1. 
ROCK family members, such as ROCK1, can regulate cell actin skeleton 
organization and cell motility by phosphorylation. Thus, ROCK1 is 
involved in tumor invasion [91,97]. In 2019, a high throughput study 
was conducted by Felgendreff et al. to detect expression profiles of 
miRNAs in HCC [86]. The study aimed to introduce miRNAs involved in 
HCC pathogenesis to be used as a promising biomarker. The results 
showed that the expression level of miR-1297 in tumor-associated 
cirrhosis was lower than cirrhosis without HCC. Therefore, no signifi-
cant relationship was observed between miR-1297 and HCC tumor [86]. 
Overall, the majority of the conducted studies suggest that miR-1297 
acts as a tumor suppressor in HCC; however, there are still some dis-
agreements. Therefore, the precise function of miR-1297 in HCC, 
particularly lncRNAs or circRNAs-miR-1297-related genes and signaling 
pathways, should be elucidated in future investigations. 
8. MiR-1297 and genitourinary cancers 
Genitourinary cancers are a general classification of those cancers 
arising from the urinary and reproductive systems in men and women. 
The most important ones include bladder, kidney, prostate, cervical, 
testicular, and ovarian cancers. CC was recently estimated to be one of 
the most common cancers in women and the third or fourth leading 
cause of cancer death worldwide. Despite significant advances in the 
diagnosis and treatment of CC, full recovery and long-term prognosis 
still remain poor. Also, the precise molecular mechanisms involved in 
CC’s initiation and progression still need to be elucidated [98]. In 2017, 
Wang et al. studied the role of miR-1297 in the tissues and cell lines of 
CC. The results showed that the expression of miR-1297 in the cell lines 
were decreased. In this regard, overexpression of miR-1297 inhibited 
migration, invasion, and EMT of cells, and downregulation of miR-1297 
reversed the tumorigenic behaviors in vitro. Bioinformatics and exper-
imental methods proved that the AEG-1 (astrocyte elevated gene-1) is a 
direct target for miR-1297. It has been reported that AEG-1 increases in 
the variety of cancers. It induces proliferation of CC cell via the signaling 
pathway of FOXO1/PI3K/AKT. Also, AEG-1 may increase EMT of CC cell 
via the signaling pathway of Wnt/β‑catenin. Finally, the study 
concluded that miR-1297 acts as a tumor suppressor by inhibiting the 
AEG-1. It has previously been shown that miR-1297 inhibits prostate 
cancer progression via suppression of the AEG-1/Wnt signaling pathway 
[98,99,130]. Also, in 2018, Chen et al. investigated the biological role of 
miR-1297 in CC. Like many other studies, they found that miR-1297 
targets PTEN. MiR-1297 expression in CC tissues was lower than 
normal tissue, and PTEN expression was negatively correlated with 
miR-129. Furthermore, overexpression of miR-1297 was shown to 
inhibit proliferation and induce apoptosis in vitro. The PTEN silencing 
also had the same effects. It was concluded that miR-1297 could reduce 
cell proliferation by suppressing the PTEN expression[100]. However, 
many studies have reported controversial results regarding PTEN func-
tion [77,101,102]. 
TGCT is another cancer that is classified as genitourinary cancer. 
TGCT is the most common cancer among young men aged 25–34 in the 
United States. The majority of TGCT patients are currently being treated 
well. However, the treatment outcome depends on early diagnosis 
before metastasis [101]. Therefore, further research into the identifi-
cation of molecular mechanisms could introduce efficient biomarkers. In 
2014, Yang et al. studied the roles of miR-1297 and PTEN on cell pro-
liferation in TGCT. Initially, it was determined that PTEN is a direct 
target for miR-1297. The results also showed that the increase in 
miR-1297 was associated with suppressing PTEN and promoting cell 
proliferation. The authors, like many others, concluded that miR-1297 
acts as an oncogene and PTEN plays a tumor suppressor role in TGCT 
[101]. In another study, Yang et al. in 2016 investigated the role of Meg3 
(maternally expressed gene 3) and miR-1297 in regulating cell growth in 
TGCT. The study showed that miR-1297 directly targets PTEN. Thus, 
miR-1297 suppresses PTEN which leads to activation of PI3K/AKT 
pathway, resulting in increased cell proliferation. It was found that the 
lncRNA-Meg3 acts as a sponge of miR-1297 and prevents the suppres-
sion of PTEN, but its expression in TGCT is significantly reduced. 
Overexpression of lncRNA-Meg3 was shown to increase PTEN and thus 
inhibit cell proliferation in TGCT [102]. 
Bladder carcinoma is another cancer that is classified as genitouri-
nary cancer. It is the most common tumor of human urinary system and 
is one of the leading causes of cancer death, worldwide. This cancer is 
more common in men and occurs in middle age or above. Histological 
types of BlC are transitional cell carcinoma or squamous cell carcinoma 
[103]. 
Peng et al. in 2021 studied the effects of miR-1297 and circ-001418 
in bladder carcinoma. The results showed that overexpression circ- 
001418 is associated with increased cell proliferation and decreased 
apoptosis. Declined expression of circ-001418 was also associated with 
inhibition of cell proliferation and promotion of apoptosis. Moreover, 
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EPH receptor A2 (EphA2) was identified as the direct target for miR- 
1297, which increases in the cancer cells. Additionally, circ-001418 
increased EphA2 expression by the suppression of miR-1297, in 
bladder carcinoma cells. EphA2 is expressed in many human cell lines 
and is considered as a regulator of cell proliferation. Therefore, it is 
involved in developing the nervous system, angiogenesis, growth, 
migration, and differentiation of cells [103,104]. 
Epithelial ovarian cancer (EOC) is another malignancy that is clas-
sified as genitourinary cancer. EOC is the most common tumor in 
women, accounting for approximately 90% of malignant ovarian tu-
mors. About 70% of the patients are diagnosed within the advanced 
stages of the disease, when the prognosis is poor [105]. Therefore, 
further studies are needed to identify biomarkers and more ideal prog-
nosticators. In this regard, Dou et al. in 2017 studied the expression of 
integrated mRNA and miRNA signatures in lymphocytes of EOC pa-
tients. The results showed that the expression of miR-1297 was 
decreased in the patients. Based on bioinformatics studies, MGEA5 and 
TAOK1 were introduced as direct targets of miR-1297. Therefore, 
miR-1297 can be employed as novel biomarkers of EOC; however, more 
studies are needed in this field [105]. According to the available studies, 
it can be concluded that the potentially tumor-suppressive or oncogenic 
role of miR-1297 in genitourinary system cancers depends on the types 
of organs. For example, miR-1297 represents a tumor-suppressive role in 
CC, but it acts as an oncogene in TGCT. Therefore, additional in-
vestigations of multiple signaling pathways that influence miR-1297 
expression levels or are affected by miR-1297 utilizing larger tissue 
specimens and various cell lines in all organs should be conducted to 
illuminate the exact function of miR-1297 in genitourinary system 
neoplasms. 
9. MiR-1297 and gastrointestinal cancer 
Gastrointestinal (GI) cancers are one of the most common cancers, 
worldwide. Common GI cancers include oral, gastric, esophageal, 
pancreatic, and colon cancers. They are often diagnosed by endoscopy, 
followed by biopsy of the target tissue. However, researchers have 
investigated some novel and non-invasive epigenetic biomarkers for GC 
within the past decade [106,107]. 
This section first looks at colon cancer, the most common malignant 
tumor of the GI tract. According to previous reports, more than one 
million new cases of CRC are diagnosed worldwide each year, and its 
mortality rate in developed countries is around 33% [108]. Its average 
annual incidence has increased by more than 5% in China from 1992 to 
2005 [84]. With more understanding of its molecular mechanisms in 
recent years, patient’s overall survival rate has improved. In 2012, 
Hamfjord et al. analyzed miRNA’s differential expression profile in CRC 
tissues and reported that miR-1297 expression was significantly reduced 
in CRC tissues [109]. In 2014, Chen et al. studied the role of miR-1297 
and cyclo-oxygenase-2 (Cox2) in the growth, migration, and invasion of 
CRC cells and noticed that miR-1297 expression was reduced, and 
conversely, Cox2 expression was elevated. MiR-1297 directly targeted 
Cox2 and leaded to suppression of Cox2 in the normal cells. Therefore, 
miR-1297, by suppressing Cox2, inhibits the growth, migration, and 
invasion of CRC cells [84]. Several articles have reported that Cox2 
promotes CRC by producing prostaglandins (PGs) and chronic inflam-
mation in cells. In 85% of CRC tissues, the Cox2 gene was up-regulated, 
and levels of PGs were increased, accordingly. PGs, especially PGE2, 
have been reported to induce proliferation, invasion, and CRC cell 
migration. It has also been shown to inhibit apoptosis and induce 
angiogenesis [84,110]. The role of redox status and miR-1297 in SP 
(stem-like side-population) cells of CRC was studied by Qiang et al. in 
2016 and according to the results, miR-1297 expression was reduced 
significantly in CRC-SP. The xCT (glutamate-cysteine transporter) 
within the plasma membrane was identified as a direct target of 
miR-1297, and its expression levels were inversely related to miR-1297 
expression in CRC-SP cells [89]. The xCT expression is increased in CRC 
and leads to reduction of ROS levels in CRC-SP cells. GSH (reduced 
glutathione) levels are increased following interaction between the xCT 
and CD44 variant leading to reduction of ROS levels in cancer cells 
which is an important modulator of cancer cell proliferation through the 
CD44v-xCT axis. Therefore, miR-1297 is a tumor suppressor and inhibits 
CRC-SP cell proliferation by decreasing GSH levels in CRC-SP cells [89, 
111]. Wang et al. in 2017 identified cyclin D2 (CCND2) as a direct target 
of miR-1297 in CRC cells. They discovered that miR-1297 expression is 
reduced in CRC cells, and conversely, CCND2 expression is significantly 
increased. The CCND2 is involved in progression of various types of 
cancer through induction of G1 cell cycle. Overexpression of miR-1297 
decreases cell proliferation and metastasis potential in SW480 cells by 
declining CCND2 expression [108]. In 2018 Yan et al. studied miRNA 
expression profile in SW480 (colon adenocarcinoma cells) and SW620 
(cell metastatic) by high-throughput methods [112]. The results showed 
that miR-1297 expression is reduced in SW620 despite SW480. Also, 
potential target genes of miR-1297 was shown to be PTEN, COX2, 
HMGA2, EZH2, TRIB2, and C/EBPalpha. The genes can be involved in 
the proliferation, invasion, and apoptosis of cells [112]. 
In this section, it is necessary to review studies on the role of miR- 
1297 in the pathogenesis of GC, which is one of the leading causes of 
cancer death, globally [113]. There are many advances in surgical and 
chemotherapy techniques for the treatment of GC with high recovery 
rates, as long as it is diagnosed timely. One of the reasons for the late 
diagnosis of GC is lack of potent prognostics [113]. To recognize more 
valuable and effective prognostics, a better understanding of the path-
ogenesis of GC is needed [114]. In this regard, Sun et al. in 2016 studied 
the effect of the lncRNA- HOXA11-AS and miR-1297 on GC tissues 
[113]. The results demonstrated that HOXA11-AS expression in GC tis-
sues was increased, and, conversely, the miR-1297 expression was 
reduced, significantly. Additionally, miR-1297 directly targeted EZH2 
and could be sponged by HOXA11-AS, leading to elevation of EZH2 
expression and induction of proliferation and invasion of GC cells. 
Therefore, miR-1297 as a tumor suppressor inhibits proliferation and 
invasion by suppressing EZH2 expression in non-cancer cells. This study 
found that the lncRNA-HOXA11-AS expression was significantly 
increased in GC tissues compared to normal tissues by sequencing and 
microarray techniques [113]. In 2017 Liu et al. studied the expression of 
lncRNA-MALAT1 and miR-1297 in GC [115]. The results showed 
MALAT1 expression was up-regulated in GC tissues, and, conversely, the 
miR-1297 expression was reduced significantly. Moreover, MiR-1297 
directly targets HMGB2 and can be sponged by MALAT1. It has been 
shown that MALAT1 increases HMGB2 expression and leads to induction 
of proliferation and invasion in GC. Therefore, 
MALAT1/miR-1297/HMGB2 axis is an important regulator of prolifer-
ation and invasion in GC tumorigenesis [115]. The effect of MALAT1 on 
various cancers has been studied and available evidence shows that it 
plays a vital role in carcinogenesis. Accordingly, MALAT1 has been 
shown to induce growth and metastasis of cancer cells through EMT in 
oral carcinoma. Also, the effect of HMGB2 on various cancers has been 
studied and its increased expression has been reported to be associated 
with the progression of HCC. On the contrary, HMGB2 knockdown 
reduced the chemo-resistance in GC cells [115,116]. In 2018 Gao et al. 
studied the role of miR-1297 and CREB1 (cAMP-responsive 
element-binding protein1) in GC [85]. They reported that miR-1297 
expression was significantly reduced in GC tissues. Furthermore, over-
expression of miR-1297 suppressed colony-forming abilities and cell 
proliferation in GC cell lines, significantly. Also, overexpression of 
miR-1297 suppressed the growth of GC tissues. In this study, CREB1 was 
identified as the target of miR-1297, and increased expression of CREB1 
promoted the growth of GC cells [85]. CREB1 has been reported as an 
oncogene on various cancers; for example, upregulation of CREB1 in GC 
was associated with metastasis. However, suppression of CREB1 could 
inhibit cell growth in human gastric adenocarcinoma [85,117]. In 2019 
Zhang et al. studied the effect of miR-1297 on proliferation and 
apoptosis of GC cells [114]. The results showed that miR-1297 
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expression was reduced in vitro and in vivo, significantly. Additionally, 
overexpression of miR-1297 suppressed colony-forming abilities and 
enhanced apoptosis in vitro. Conversely, inhibition of miR-1297 
extended colony-forming abilities and suppresses apoptosis. All of the 
miR-1297 roles are due to targeting CDC6 (cell division control protein 
6) oncogenes in GC cells [114]. CDC6 is a molecular factor which is 
essential for the initiation of DNA replication. Also, it has an important 
role in maintaining the mechanisms of the checkpoint in the cell cycle. 
CDC6 has been reported to be associated with oncogenic activity in 
human cancers. For instance, the elevation of CDC6 could increase cell 
proliferation, in ovarian cancer. CDC6 may be an appropriate thera-
peutic target for reducing chemo-resistance in BC [114,118]. In 2021 
Wang et al. studied the roles of miR-1297 and circ_PGPEP1 in GC [131]. 
They found that knockdown of circ_PGPEP1 increased apoptosis and 
reduced proliferation, invasion, and migration of GC cells. Additionally, 
miR-1297 targeted E2F3 (E2F transcription factor 3) and thus sup-
pressed its expression in normal cells. However, circ_PGPEP1 sponged 
miR-1297 and thereby increased E2F3 expression in GC cells [131]. The 
transcriptional regulatory family of E2F has an important effect on 
tumorigenesis biological behaviors, including cell cycle, apoptosis, and 
proliferation. Some studies have reported that E2F3 is increased in 
different types of cancer, especially in GC cells; it leads to increased cell 
proliferation and metastasis [108,119]. In 2020 Wu et al. investigated 
the mRNA polymorphisms (SNP) in human GC to identify novel bio-
markers for the diagnosis and screening [120]. MiR-1297 rs9536676 
polymorphism was found to be significantly associated with suscepti-
bility to GC risk. Therefore, miR-1297 rs9536676 polymorphism can be 
used as a novel biomarker for GC [120]. 
Another GI cancer is ESCC which is the eighth most common cancer 
and the sixth leading cause of cancer death in the world. The incidence 
of ESCC depends on the age and gender of the individual. In 2016, it was 
reported that about 90% of its prevalence is in China and other countries 
in the East Asian region [88]. Despite advances in treatment and diag-
nosis in recent years, the response to treatment is still unsatisfactory and 
molecular studies are still needed to identify new biomarkers. In 2016 
Wang et al. evaluate the diagnostic potential of serum miR-1297 in 
patients with ESCC and noticed that miR-1297 level was statistically 
lower than the normal group [88]. Therefore, serum miR-1297 can be 
used as an ideal biomarker for the diagnosis of ESCC [88]. 
Another GI cancer is oral OSCC which is the sixth most common 
malignancy globally and accounts for 90% of all oral cancers [121]. It is 
also known as one of the most common head and neck cancers which the 
incidence is increasing, especially in younger people [122]. Therefore, 
the diagnostic and therapeutic measures should urgently be adopted. In 
this regard, Liang et al. in 2018 studied the biological role of miR-1297 
and PTEN in OSCC [121]. The results showed that miR-1297 expression 
was suppressed in OSCC tissues, and conversely, PTEN expression was 
up-regulated. It was also reported that overexpression of miR-1297 and 
PTEN knockdown reduces OSCC cell growth rate in vitro. There have 
been many studies on the effect of PTEN on tumorigenesis, and con-
flicting results have been reported, but this is the only article that in-
vestigates its effect on OSCC [77,100,101,121]. Furthermore, Gao et al. 
in 2019 studied the role of miR-1297 and lncRNA GAS5 (growth 
arrest-specific 5) on cell apoptosis in OSCC [122]. The results showed 
that miR-1297 expression level was elevated in the cancerous cells and 
following treatment with propofol (anesthetic drug), GAS5 was upre-
gulated and through sponging miR-1297 increased GSK3β expression 
which identified as a direct target for miR-1297. Moreover, it was 
discovered that Mcl1, is an anti-apoptosis protein, and GSK3β could 
decrease Mcl1 protein in the cells. Therefore, propofol through 
GAS5/GSK3β axis induced anti-tumor effect in OSCC cells. Several 
studies have reported that GAS5 has tumor suppressor effects in 
different cancers [122,123]. In another study conducted by Li et al., the 
oncogenic role of GAS5 in CCA was confirmed. They determined that the 
expression level of GAS5 was up-regulated in CCA tissue compared to 
adjacent tissue which was associated with lymph node metastasis. Also, 
functional analyses revealed that GAS5 promoted invasion and cell 
proliferation through sponging miR-1297, in vitro [63]. In general, the 
majority of researches indicate that miR-1297 acts as a tumor suppressor 
in GI cancers. Accordingly, it might be employed as a potential diag-
nostic, prognostic and therapeutic tool for GI neoplasms. 
10. MiR-1297 and other malignancies 
Pancreatic cancer is a malignant, highly invasive, and metastatic 
tumor which is considered as the seventh leading cause of cancer-related 
mortality globally, with higher occurrence in developed countries. Lack 
of proper diagnosis, therapy, and cataloging strategies leads to variable 
mortality rates in these patients. Considering that the individuals are 
asymptomatic till the advanced stage of the illness, it remains one of the 
fatal malignancies that caused 466,003 deaths in 2020 (GLOBOCAN 
2020 estimates) [69,124]. Thus, it is required to explore the exact mo-
lecular mechanisms of pancreatic cancer to develop novel diagnostic 
and reliable treatment strategies. In this regard, Chen et al. in 2018 
reported downregulation of miR-1297 and upregulation of metadherin 
(MTDH) as a direct target of miR-1297 in pancreatic adenocarcinoma 
tissues and cells compared to paired adjacent normal tissues and control 
cell lines. Additionally, they proved that overexpression of miR-1297 or 
knockdown of MTDH causes suppression of cell apoptosis and decreases 
cell proliferation, migration, and metastasis. Therefore, it can be said 
that the miR-1297/MTDH pathway is an innovative diagnostic tool and 
possible therapeutic target for patients with pancreatic cancer [124]. 
Bones and joints tumors are responsible for 1660 deaths in the 
United States in 2019. OS is the most commonly diagnosed primary bone 
tumors which is usually reported in adolescents and children, and 
overall survival in OS patients has remained approximately steady for 
over two decades. However, remarkable progressions have been made in 
the diagnosis and therapy of OS [11]; thus, exploring the mechanism 
underlying OS development and investigating the useful therapeutic 
targets are of grave importance. Recent researches suggest that 
miR-1297 represents a tumor-suppressive function in OS. With this 
aspect, Pan et al. in 2020 assessed the diminished expression of 
miR-1297 in human OS tissue specimens associated with the advanced 
pathological staging and cell lines. They showed that lower expression of 
miR-1297 promotes cell proliferation correlated with Warburg effect. 
The remarkable increase in glucose uptake and the generation of lactate 
even in the presence of oxygen and entirely functional mitochondria in 
tumors or other cells under development is known as the Warburg effect. 
The process plays a central role in supporting proliferation, aggres-
siveness, and drug resistance of OS. The enzyme fructose-2, 6-bisphos-
phatase 2 (PFKFB2), as a bifunctional enzyme, regulates fructose 2, 
6-bisphosphate (Fru-2,6-P2) and previous researches have demon-
strated significant upregulation of PFKFB2 in numerous tumors that 
improves glycolysis and proliferation. Notably, they demonstrated that 
overexpression of miR-1297 suppressed aerobic glycolysis evidenced by 
reduced ECAR as an index of glycolytic rate and lactate production as 
well as enhanced mitochondrial respiration (OCR) and ATP production. 
Moreover, the upregulation of miR-1297 decreased cell proliferation 
and induced cell apoptosis via inhibiting PFKFB2 as a direct target gene. 
In contrast, overexpression of PFKFB2 diminished all the above 
mentioned anti-tumor effect of miR-1297. Collectively their study pro-
posed that miR-1297 could be a possible tool for OS therapy [125]. 
MM is the most malignant and fatal skin tumor that stems from the 
unlimited proliferation of melanocytes-pigment-producing cells and is 
known to distant metastasis. The most frequent MM form is cutaneous; 
however, it can be found in other parts including mucosal surfaces, the 
uveal tract, and leptomeninges. Considering that MM’s global incidence 
has increased quickly over the last 50 years, exploring precise mecha-
nisms involved in regulation of gene expression during metastases is 
essential for improving efficient therapeutic strategies in metastatic MM. 
Firm evidence revealed that dysregulation of miRNAs executes a crucial 
function in the expansion and progression of MM. In this regard, Han 
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et al. in 2019 noticed that miR-1297 is upregulated in MM tissues and 
cells compared to those of control. They also found that the regulation 
was associated with the advanced tumor-node-metastasis (TNM) stage 
in patients with MM suggesting possible oncogenic roles of miR-1297. 
Moreover, they showed that anit-miR-1297 suppresses cell viability 
evidenced by the downregulation of Ki67 protein and can inhibit EMT 
progression in vitro through up-regulating PTEN as a tumor suppressor. 
EMT plays a vital role in embryonic development, chronic inflammation, 
tissue remodeling, cancer metastasis, and multiple fibrotic disorders. 
Reducing the expression of cell adhesion molecules such as E-cadherin, 
promoting N-cadherin expression, and improving the conversion of 
cytoskeletal proteins to Vimentin are the principal hallmarks of EMT. 
Interestingly, Han et al. documented that in MM cell lines treated with 
anti-miR-1297, E-cadherin’s protein level was reduced. However, N- 
cadherin’s protein level and Vimentin were increased by preventing 
miR-1297 with its target-PTEN. In conclusion, miR-1297 might be a new 
therapeutic target for MM, and anti-miR-1297 can be considered as a 
novel gene therapy molecule [11,126,127]. In line with these findings, 
Wang et al., in 2021, reported that anti-miRNA‑1297 restrains cell in-
vasion and migration of PC through upregulating PTEN and repressing 
the AKT/ERK signaling pathway [128]. 
11. Conclusions 
In summary, the available studies indicate that miR-1297 is both 
upregulated and downregulated in different cancers. It also plays a dual 
role in various malignancies, as sometimes it is a tumor suppressor, and 
on other occasions, it is an oncogene. This huge controversy deserves 
further investigation in future studies. Particularly the current research 
is mainly limited to cell culture and clinical tissue samples. However, 
more clinically oriented studies using animal models are required to 
elucidate the precise role of miR-1297 in different cancers. 
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